| Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer R Condorelli, L Spring, J O’shaughnessy, L Lacroix, C Bailleux, V Scott, ... Annals of Oncology 29 (3), 640-645, 2018 | 306 | 2018 |
| Treatment strategies for breast cancer brain metastases C Bailleux, L Eberst, T Bachelot British journal of cancer 124 (1), 142-155, 2021 | 186 | 2021 |
| Matrix stiffening and EGFR cooperate to promote the collective invasion of cancer cells EM Grasset, T Bertero, A Bozec, J Friard, I Bourget, S Pisano, ... Cancer Research 78 (18), 5229-5242, 2018 | 94 | 2018 |
| Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study D Chardin, M Paquet, R Schiappa, J Darcourt, C Bailleux, M Poudenx, ... Journal for immunotherapy of cancer 8 (2), 2020 | 66 | 2020 |
| External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience G Griguolo, W Jacot, E Kantelhardt, MV Dieci, C Bourgier, C Thomssen, ... The Breast 37, 36-41, 2018 | 41 | 2018 |
| Comparison of unsupervised machine-learning methods to identify metabolomic signatures in patients with localized breast cancer J Gal, C Bailleux, D Chardin, T Pourcher, J Gilhodes, L Jing, JM Guigonis, ... Computational and Structural Biotechnology Journal 18, 1509-1524, 2020 | 37 | 2020 |
| Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer A Darlix, G Griguolo, S Thezenas, E Kantelhardt, C Thomssen, MV Dieci, ... Journal of Neuro-Oncology 138, 369-382, 2018 | 25 | 2018 |
| Concomitant cervical and transperineal parametrial high-dose-rate brachytherapy boost for locally advanced cervical cancer C Bailleux, AT Falk, ME Chand-Fouche, M Gautier, E Barranger, ... Journal of contemporary brachytherapy 8 (1), 23-31, 2016 | 22 | 2016 |
| Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib C Bailleux, G Robert, C Ginet, D Re, A Thyss, I Sudaka, I Peyrottes, ... Oncoscience 2 (1), 44, 2015 | 19 | 2015 |
| Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations B Kingston, C Bailleux, S Delaloge, G Schiavon, V Scott, M Lacroix-Triki, ... JCO precision oncology 3, 1-7, 2019 | 16 | 2019 |
| Using methylation signatures on cell-free DNA for early cancer detection: a new era in liquid biopsy? C Bailleux, L Lacroix, E Barranger, S Delaloge Annals of Oncology 31 (6), 665-667, 2020 | 9 | 2020 |
| Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program D Bello Roufai, A Goncalves, T De La Motte Rouge, S Akla, C Blonz, ... Oncogene 42 (23), 1951-1956, 2023 | 8 | 2023 |
| Factors involved in delaying initiation of adjuvant chemotherapy after breast cancer surgery C Meyer, C Bailleux, E Chamorey, R Schiappa, Y Delpech, M Dejode, ... Clinical Breast Cancer 22 (2), 121-126, 2022 | 7 | 2022 |
| Prevention of brain metastases in human epidermal growth factor receptor 2-positive breast cancer L Eberst, C Bailleux, T Bachelot Current Opinion in Oncology 32 (6), 555-560, 2020 | 7 | 2020 |
| RUBY: Natural language processing of french electronic medical records for breast cancer research R Schiappa, S Contu, D Culie, B Thamphya, Y Chateau, J Gal, C Bailleux, ... JCO Clinical Cancer Informatics 6, e2100199, 2022 | 6 | 2022 |
| Efficacy of tucatinib+ trastuzumab+ capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre … JS Frenel, J Zeghondy, C Guerin, A Mailliez, E Volant, F Poumeaud, ... Journal of Clinical Oncology 41 (16_suppl), 1014-1014, 2023 | 5 | 2023 |
| Artificial Intelligence and Anticancer Drug Development—Keep a Cool Head C Bailleux, J Gal, E Chamorey, B Mograbi, G Milano Pharmaceutics 16 (2), 211, 2024 | 3 | 2024 |
| Primal-dual for classification with rejection (PD-CR): a novel method for classification and feature selection—an application in metabolomics studies D Chardin, O Humbert, C Bailleux, F Burel-Vandenbos, V Rigau, ... BMC bioinformatics 22 (1), 594, 2021 | 3 | 2021 |
| LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2-early-stage breast cancer at very low risk of metastasis. E Deluche, S Michiels, D Fric, C Perrin, C Bailleux, T Bachelot, ... Journal of Clinical Oncology 41 (16_suppl), TPS615-TPS615, 2023 | 2 | 2023 |
| Validation of RUBY for Breast Cancer Knowledge Extraction From a Large French Electronic Medical Record System R Schiappa, S Contu, D Culie, Y Chateau, J Gal, T Pace-Loscos, ... JCO Clinical Cancer Informatics 7, e2200130, 2023 | 2 | 2023 |
